SCHEMBL6136358

SCHEMBL6136358

CCN(Cc1ccc(Cc2c(-c3ccc(O)cc3)ccc3cc(O)ccc23)cc1)C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 2/20 0.43
▸ ROCK2 O75116 1/20 0.42
▸ CCR1 P32246 2/20 0.41
▸ EGFR P00533 4/20 0.41
▸ ERBB2 P04626 4/20 0.41
▸ ESR1 P03372 3/20 0.41
▸ ESR2 Q92731 3/20 0.41
▸ GAA P10253 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 2/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136065 0.95 TRPV1 (0.47) TRPV1ROCK2EGFRERBB2ESR1
SCHEMBL6136144 0.92 TRPV1 (0.44) TRPV1ROCK2EGFRERBB2ESR1
SCHEMBL6136103 0.90 ESR1 (0.45) TRPV1ROCK2ESR1ESR2MAPT
SCHEMBL6136478 0.89 MTOR (0.48) TRPV1ROCK2CCR1EGFRERBB2
SCHEMBL6135989 0.85 GAA (0.40) TRPV1ROCK2ESR1ESR2GAA
SCHEMBL6136113 0.84 TRPV1 (0.52) TRPV1EGFRERBB2ESR1ESR2
SCHEMBL6136341 0.84 MTOR (0.53) TRPV1ROCK2EGFRERBB2ESR1
SCHEMBL6136177 0.81 MTOR (0.49) TRPV1ROCK2CCR1EGFRERBB2
SCHEMBL6136280 0.81 ERCC1 (0.49) TRPV1ESR1ESR2MEN1KMT2A
SCHEMBL6135968 0.80 TRPV1 (0.41) TRPV1ROCK2EGFRERBB2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback